All Comments by Gil Rabinovici
Go to another page:
- 1
- 2
- Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD
- CSF MTBR-tau-243 Tracks Tangles, Plummets in Response to Antibody
- And Then There Were Three: Donanemab Phase 3 Trial Positive
- Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline Results
- In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy
- Amyloid Lurks in a Third of Cognitively Normal People Over 70
- CMS Plans to Limit Aduhelm Coverage to Clinical Trials
- Doubling of Tau Seeds, Not Spread, Sets Pace of Tauopathy in Alzheimer's
- Flock of New Folds Fills in Tauopathy Family Tree
- Aducanumab: Will Appropriate-Use Recommendations Speed Uptake?
- Aducanumab Approved to Treat Alzheimer’s Disease
- Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
- Aducanumab Still Needs to Prove Itself, Researchers Say
- PET Identifies Tangles Decades after a Single Traumatic Brain Injury
- Colleagues Mourn Loss of Rahul Desikan, Age 41, to ALS